Mo-Rez in First- Line (1L) Maintenance Treatment of Non- Homologous Recombination Deficient Ovarian Cancer (HRd OC) [BEHOLD-Ovarian03]

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) alone or in combination with bevacizumab works in treating ovarian cancer compared to bevacizumab alone or active observation (AO). The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to bevacizumab alone OR AO and will help provide a better understanding of the main side effects of the drugs.

NCT Number	NCT07694427
Lead Sponsor	GlaxoSmithKline Collaborators: ENGOT, GOG, APGOT
Conditions	Ovarian Neoplasms
Enrollment	720 participants
Start Date	2026-10-09
Primary Completion	2029-09-06 (estimated)
Study Completion	2032-11-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-15